While neither rs4969239 nor rs9913477 was validated, when meta-analyzed with the original dataset their association with BC remained directionally consistent (OR = 1.29, 95% CI = 1.16-1.44 (p = 4.18 × 10<sup>-6</sup>) and OR = 1.33, 95% CI = 1.17-1.51 (p = 1.6 × 10<sup>-5</sup>), respectively).
While neither rs4969239 nor rs9913477 was validated, when meta-analyzed with the original dataset their association with BC remained directionally consistent (OR = 1.29, 95% CI = 1.16-1.44 (p = 4.18 × 10<sup>-6</sup>) and OR = 1.33, 95% CI = 1.17-1.51 (p = 1.6 × 10<sup>-5</sup>), respectively).
While neither rs4969239 nor rs9913477 was validated, when meta-analyzed with the original dataset their association with BC remained directionally consistent (OR = 1.29, 95% CI = 1.16-1.44 (p = 4.18 × 10<sup>-6</sup>) and OR = 1.33, 95% CI = 1.17-1.51 (p = 1.6 × 10<sup>-5</sup>), respectively).
While neither rs4969239 nor rs9913477 was validated, when meta-analyzed with the original dataset their association with BC remained directionally consistent (OR = 1.29, 95% CI = 1.16-1.44 (p = 4.18 × 10<sup>-6</sup>) and OR = 1.33, 95% CI = 1.17-1.51 (p = 1.6 × 10<sup>-5</sup>), respectively).
For case-control study, chi-square tests provided evidence for the contribution of SNP rs4969239, rs3934492 and rs4969385 to ADHD and its two clinical subtypes, ADHD-I and ADHD-C.
For case-control study, chi-square tests provided evidence for the contribution of SNP rs4969239, rs3934492 and rs4969385 to ADHD and its two clinical subtypes, ADHD-I and ADHD-C.
For case-control study, chi-square tests provided evidence for the contribution of SNP rs4969239, rs3934492 and rs4969385 to ADHD and its two clinical subtypes, ADHD-I and ADHD-C.